Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life
- PMID: 10561188
- DOI: 10.1200/JCO.1999.17.4.1267
Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life
Abstract
Purpose: To examine the safety, efficacy, costs, and impact on quality of life of venous access ports implanted at the outset of a course of intravenous cancer chemotherapy.
Patients and methods: Adults beginning a course of intravenous chemotherapy at two university-affiliated hospitals were randomly allocated to have venous access using a surgically implanted venous access port (Port-a-Cath; Pharmacia, Canada Inc, Montreal, Québec, Canada) or using standard peripheral venous access. All accesses were documented by number, route, purpose, and procedure duration. Outcome measurements included port complications, access strategy failure, access-related anxiety and pain, quality of life (Functional Living Index-Cancer [FLI-C]), and costs.
Results: Port complication rates were low (0.23/1,000 days). Failure occurred in two (3.4%) of 59 port subjects and 16 (26.7%) of 60 controls (P =. 0004) at a median period of 26 days after randomization (95% confidence interval, 8 to 92). Peripheral accesses in port subjects took less time, had less access-related anxiety and pain, and were less costly to perform than in controls. Allocation had no effect on FLI-C scores. Peripheral access failure correlated with allocation to the control group (P =.007), higher pain scores with intravenous (IV) starts (P =.003), and anxiety with IV starts (P =.01). Venous accessing overall in port patients was four times more costly than that in controls ($2,178/patient v $530/patient, respectively).
Conclusion: Ports were safe and effective but had no detectable impact on functional quality of life, despite less access-related anxiety, pain, and discomfort. Because only approximately one quarter of control patients ultimately required central venous access, economic considerations suggest that port-use policies should be based upon defined criteria of need.
Similar articles
-
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.Ann Oncol. 1998 Jul;9(7):767-73. doi: 10.1023/a:1008392423469. Ann Oncol. 1998. PMID: 9739444
-
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.Eur J Cancer. 1997 Jul;33(8):1190-4. doi: 10.1016/s0959-8049(97)00039-7. Eur J Cancer. 1997. PMID: 9301441 Clinical Trial.
-
[Experience with implanted ports for venous access between 2005 and 2012].Orv Hetil. 2014 Jun 22;155(25):986-92. doi: 10.1556/OH.2014.29946. Orv Hetil. 2014. PMID: 24936574 Hungarian.
-
Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman.Sultan Qaboos Univ Med J. 2021 Feb;21(1):e103-e109. doi: 10.18295/squmj.2021.21.01.014. Epub 2021 Mar 15. Sultan Qaboos Univ Med J. 2021. PMID: 33777430 Free PMC article. Review.
-
Complications and Costs of Peripherally Inserted Central Venous Catheters Compared With Implantable Port Catheters for Cancer Patients: A Meta-analysis.Cancer Nurs. 2020 Nov/Dec;43(6):455-467. doi: 10.1097/NCC.0000000000000742. Cancer Nurs. 2020. PMID: 31464692
Cited by
-
Incidents and complications of permanent venous central access systems: a series of 1,460 cases.Korean J Thorac Cardiovasc Surg. 2014 Apr;47(2):117-23. doi: 10.5090/kjtcs.2014.47.2.117. Epub 2014 Apr 10. Korean J Thorac Cardiovasc Surg. 2014. PMID: 24782960 Free PMC article.
-
Does the Implantation Technique for Totally Implantable Venous Access Ports (TIVAPs) Influence Long-Term Outcome?World J Surg. 2016 Feb;40(2):284-90. doi: 10.1007/s00268-015-3233-z. World J Surg. 2016. PMID: 26341511
-
Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy.Support Care Cancer. 2016 Apr;24(4):1857-63. doi: 10.1007/s00520-015-2969-1. Epub 2015 Oct 10. Support Care Cancer. 2016. PMID: 26454864
-
Machine learning risk prediction model for bloodstream infections related to totally implantable venous access ports in patients with cancer.Asia Pac J Oncol Nurs. 2024 Jun 22;11(8):100546. doi: 10.1016/j.apjon.2024.100546. eCollection 2024 Aug. Asia Pac J Oncol Nurs. 2024. PMID: 39148936 Free PMC article.
-
Arm port vs chest port: a systematic review and meta-analysis.Cancer Manag Res. 2019 Jul 3;11:6099-6112. doi: 10.2147/CMAR.S205988. eCollection 2019. Cancer Manag Res. 2019. PMID: 31308748 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical